← Back to Analyst Consensus 
CLRB Buy
Cellectar Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Mar 10, 2026 | Maxim Group | upgrade | Hold → Buy | — | 42% |
| May 14, 2025 | Maxim Group | downgrade | Buy → Hold | $0 | 42% |
| Dec 11, 2024 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Nov 19, 2024 | Oppenheimer | maintain | Outperform → Outperform | $12 | 52% |
| Mar 28, 2024 | Roth MKM | maintain | Buy → Buy | $28 | 52% |
| Mar 28, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $12 | 52% |
| Mar 4, 2024 | Roth MKM | reiterate | Buy → Buy | $20 | 52% |
| Nov 4, 2022 | HC Wainwright & Co. | maintain | — → Buy | $4 | 44% |
Price Target Trend
Apr 14, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days